Opthea WKN: A2AB8J ISIN: AU000000OPT2 Kürzel: UKJ Branche: Gesundheit, Biotechnologie
|
|
Themen zum Wert | ||
|---|---|---|---|
| 1 | OPTHEA LTD Hauptdiskussion |
Kursdetails
| Geld (bid) | 0,352 (4.000) |
|---|---|
| Brief (ask/offer) | 0,414 (4.000) |
| Spread | 14,976 |
| Geh. Stück | 0 |
| Eröffnung | 0,352 |
| Vortag | 0,388 |
| Tageshoch | 0,352 |
| Tagestief | 0,352 |
| 52W Hoch | 0,476 |
| 52W Tief | 0,158 |
Tagesvolumen
| in USD gehandelt | 130 Stk |
|---|---|
| in EUR gehandelt | 0 Stk |
| in AUD gehandelt | 0 Stk |
| Gesamt | 130 Stk |
Partner-News
Anzeige12:31 Uhr • Partner • Societe Generale
12:00 Uhr • Partner • HSBC
11:01 Uhr • Partner • Societe Generale
11:00 Uhr • Partner • onemarkets Blog
11:00 Uhr • Partner • BNP Paribas
Aktien-News
14:05 Uhr • Artikel • dpa-AFX
14:04 Uhr • Artikel • dpa-AFX
14:03 Uhr • Meldungen • IRW-News
14:03 Uhr • Artikel • dpa-AFX
14:00 Uhr • Meldungen • EQS News
Geld/Brief Kurse
Neu laden| Börse | Geld | Vol. | Brief | Vol. | Zeit | Vol. ges. | Kurs |
|---|---|---|---|---|---|---|---|
| Nasdaq OTC | 1700000400 14. Nov | 130 Stk | 0,290 USD | ||||
| Frankfurt | 0,352 | 4.000 Stk | 0,414 | 4.000 Stk | 1714111389 08:03 | 0,352 EUR | |
| Sydney | 1713939053 24. Apr | 0,675 AUD | ges. 130 Stk |
Börsennotierung
| Marktkapitalisierung in EUR |
|---|
| 181,3 Mio. |
| Anzahl der Aktien |
| 467,2 Mio. |
Termine
| 29.08.2024 | Quartalsmitteilung |
|---|---|
| 02/25 | Quartalsmitteilung |
Grundlegende Daten zur OPTHEA LTD Aktie
| Finanzdaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|
| KUV | 7.246,00 | 7.451,00 | 3.347,00 | 1.639,67 | - | - | - |
| Ergebnis je Aktie (bereinigt) | -0,05 | -0,16 | -0,26 | -0,36 | -0,36 | - | - |
| Cashflow | -8,8 Mio. | -61,1 Mio. | -98,4 Mio. | -0,2 Mrd. | - | - | - |
| Eigenkapitalquote | 90,15 % | 97,74 % | 79,90 % | - | - | - | - |
| Verschuldungsgrad | 10,92 | 2,31 | 25,16 | - | - | - | - |
| EBIT | -25,4 Mio. | -53,2 Mio. | -0,1 Mrd. | -0,2 Mrd. | - | - | - |
| Fundamentaldaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
| KCV | -72,46 | -9,31 | -5,02 | -1,64 | - | - | - |
| Kurs-Gewinn-Verhältnis (KGV) | -43,48 | -9,31 | -3,86 | -1,37 | -1,71 | - | - |
| Bilanzdaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
| Umsatzerlöse | 87.075 | 91.981 | 125 Tsd. | 161 Tsd. | - | - | - |
| Ergebnis vor Steuern | -25,1 Mio. | -67,4 Mio. | -0,1 Mrd. | -0,2 Mrd. | - | - | - |
| Steuern | -8,5 Mio. | -6,6 Mio. | -8,7 Mio. | -8,8 Mio. | - | - | - |
Info OPTHEA LTD Aktie
Opthea
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The companys development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.